Compare Dolby Laboratories, Inc. (DLB) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Dolby Laboratories, Inc. trades at $58.67 (market cap $5.47B), while Vertex Pharmaceuticals Incorporated trades at $510.6 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.3× Dolby Laboratories, Inc.'s market cap, and Dolby Laboratories, Inc. pays a 2.46% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| DLB | VRTX | |
|---|---|---|
Market Cap | $5.47B | $127.55B |
Volume | 1,058,284 | 1,487,944 |
Sector | Technology | Health |
52-Week High | $70.09 | $557.96 |
52-Week Low | $48.51 | $407.37 |
Typical Hold Time | 98 Days | 120 Days |
Enterprise Value | $4.85B | $121.68B |
Dividend Yield | 2.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dolby Laboratories (DLB) trades at $58.67, up 0.55% with a bearish technical signal despite recent earnings beats. The company maintains strong profitability with 87.61% gross margins and 16.7% net income margins, though revenue has remained flat around $1.3B. Recent developments include expanded partnerships with Meta and leadership transition to new CEO Marc Whitten.
DLB offers value with analyst consensus target of $90.33 (54% upside) but faces near-term execution risks and licensing volatility. The stock trades at reasonable valuations (P/E 24.87, P/S 4.15) with solid cash flow generation, though technical indicators suggest caution amid bearish momentum signals.
Vertex Pharmaceuticals (VRTX) trades at $509.98, up 0.86% today, with a bearish technical signal but strong fundamentals. The company reported $12.00B revenue in 2025 with a 35% net income margin and robust cash flow. Recent positive Phase 2b data for inaxaplin in kidney disease and dominant cystic fibrosis market position support growth. Analysts maintain a strong buy consensus with a $573.50 price target, indicating 12% upside potential.
Outlook remains positive driven by pipeline expansion and high profitability, though risks include clinical trial outcomes and market volatility. The stock's valuation at 29.31 P/E is reasonable for its growth profile, but investor sentiment is cautious near-term due to mixed earnings beats and technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
